It has been reported that IFN-g-producing CD8
Introduction

Naive CD4
+ and CD8 + T cells can differentiate into IFNc-producing T h 1/IFN-c-producing CD8 + T (Tc1) cells or IL-4-producing Th2/Tc2 cells by epigenetic changes (1) . We have initially demonstrated the critical role of tumor-specific T h 1 and T h 2 cells for inducing anti-tumor immunity and proposed that T h 1/Tc1 cell circuit, but not Th2/Tc2 circuit, is critical for the generation of tumor-specific CTL during tumor eradication in vivo (2, 3) . It has been well accepted that dendritic cell/CD4 + T-cell interaction in IL-12/IFN-c axis plays an important role for overcoming immunosuppressive tumor escape mechanisms to induce T h 1-dependent CTL generation in tumor-bearing host (4, 5) . However, it is difficult to induce T h 1-dominant immunity at tumor local sites because of the existence of tumor-escape mechanisms such as signal of transducer and activator of transcription 3 (STAT3)-dependent immunosuppressive factors (6) .
Recently, it has been demonstrated that IL-17-producing T h 17 and IL-17-producing CD8 + T (Tc17) cells were induced from naive CD4 + and CD8 + T cells in the presence of TGF-b and IL-6, which are highly produced in the tumor microenvironment (7, 8) . Although IL-17 and IL-17-producing T cells have been demonstrated to be tumor-promoting factors, the role of T h 17 or Tc17 cells in tumor immunity is still controversial since some studies showed that IL-17 enhanced anti-tumor CTL responses leading to tumor regression (9) . Especially, adoptive transfer of tumor antigen-specific Tc17 cells into tumor-bearing mice exhibited potent anti-tumor activities in an IFN-c-dependent manner (10) (11) (12) . Indeed, it has been demonstrated that Tc17 cells were plastically converted into IFNc-producing Tc1-like cells to act as anti-tumor effector cells or pathogenic effector cells (10) . In addition to IFN-c-producing Tc1-like cells, IL-17/IFN-c double-producing Tc cells (Tc17/ IFN-c) have been identified in immune diseases in human and animals, similar as in T h 17 cells (13, 14) . However, there is no direct evidence that Tc17/IFN-c cells exhibit cytotoxicity and play a crucial role in tumor immunity and autoimmunity. Thus, it is important to reveal the precise function of Tc17 cell subset for evaluating whether Tc17-mediated immune responses act as anti-tumor or protumor effector cells in tumorbearing hosts.
To resolve this issue, we developed an IL-12-mediated method to convert Tc17 cells into IFN-c-producing Tc17 cells. In this report, we initially indicate direct evidence that the isolated Tc17/IFN-c cells, but not IL-17 single-producing CD8 + T cells, exhibited strong cytotoxicity against tumor cells, similar to IFN-c single-producing Tc1-like cells derived from Tc17 cells. Thus, our findings propose a novel CTL subset, Tc17/ IFN-c cell, plastically converted from Tc17 by IL-12, which might play a critical role in the tumor microenvironment.
Methods
Mice
C57BL/6 mice were purchased from Charles River Laboratories. OT-1 TCR transgenic mice were provided by F.R. Carbone (University of Melbourne, Victoria, Australia). C57BL/6-background Ly5.1 mice were purchased from RIKEN Bioresource Center. IL-17A-enhanced green fluorecent protein (EGFP) knock-in mice were purchased from Biocytogen (Worcester, MA, USA). All mice used in the present studies were 5-to 8-week old and maintained in specific pathogenfree conditions according to the guidelines for animal care of our institute and were used in accordance with the guidance of an institutional committee at Hokkaido University.
Reagents
Recombinant murine IL-2 was kindly donated by Dr T. Sawada (Shionogi Pharmaceutical Institute Co., Osaka, Japan). Recombinant human TGF-b1 and recombinant murine IL-12 were purchased from Wako Pure Chemical Industries (Osaka, Japan). Recombinant human IL-6 was kindly supplied by Chugai Pharmaceutical Company Ltd (Shizuoka, Japan). Recombinant murine IFN-c was purchased from Pepro Tech EC Ltd (London, UK). Recombinant murine IL-23 was purchased from R&D Systems (Minneapolis, MN, USA). Neutralizing mAb against IFN-c (R4-6A2, donated by Dr G. Trinchieri, Wistar Institute of Anatomy and Biology, Philadelphia, PA, USA) and IL-4 (11B11, American Type Culture Collection, Rockville, MD, USA) were purified from ascites fluid of mice in our laboratories. Recombinant ovalbumin (OVA)257-264 peptide was kindly supplied by Dr H. Tashiro (Fujiya Co. Ltd, Hadano, Kanagawa, Japan).
Generation of CD8 + T-cell subsets
Erythrocyte-eliminated single-cell suspension was passed through a nylon wool column for enrichment of T cells and were stained with FITC-CD44 mAb (IM7; eBioscience, San Diego, CA, USA), PE-CD62L mAb (MEL-14; eBioscience) and PE-Cy7-CD8a mAb (53-6.7; BD Biosciences, San Jose, CA, USA). CD44 low CD62L + naive CD8 + T cells were isolated using a cell-sorting system (FACSAria; BD Biosciences). For generation of Tc17 cells, OT-1 naive CD8
+ T cells were stimulated with OVA257-264 peptide (5 lg ml 
Cytotoxicity assay
The cytotoxicity mediated by tumor-specific CTLs was measured by a 4-to 8-h 51 Cr-release assay as described previously (15) . Tumor-specific cytotoxicity was determined using EG-7 cells (OVA gene-transfected EL-4 cells) as targets. Parental EL-4 cells were used as control targets. The percent cytotoxicity was calculated as described previously (15) .
Quantitative PCR
Total RNA was extracted from the cells using the Isogen RNA extraction kit (Nippongene Co., Ltd, Tokyo, Japan). cDNA was prepared using Superscript lll RT (Invitrogen, Fredrick, MD, USA). The indicated gene cDNAs were specifically amplified using a LightCycler system (Roche Applied Science, Indianapolis, IN, USA) and corresponding primer pairs and probes. Primer and probe sequences for mouse IL-17A, IFN-c and b-actin are described previously (16) . Primer and probe (numbers indicated are from the list of Universal ProbeLibrary Set; Roche Applied Science) used were as follows: Perforin, sense primer, 5#-AATATCAATAACGACTGGCGTGT-3#, antisense primer, 5#-CATGTTTGCCTCTGGCCTA-3#, probe#42; Granzyme B, sense primer, 5#-AGGGGGTACAAGGTCACAGA-3#, antisense primer, 5#-CAAGAGTGTTGTCCTTGCTCTCT-3#, probe#13; T-bet, sense primer, 5#-TCAACCAGCACCAGA-CAGAG-3#, antisense primer, 5#-AAACATCCTG-TAATGGCTTGTG-3#, probe#19; and RORct, sense primer, 5#-ACCTCCACTGCCAGCTGTGTGCTGTC-3#, antisense primer, 5#-TCATTTCTGCACTTCTGCATGTAGACTGTC-3#, probe#21. Samples were normalized to the housekeeping gene b-actin according to the nnCt method: nCt = nCt sample -nCt reference .
Adoptive tumor immunotherapy
EG-7 cells (2 3 10 6 ) were intradermally (i.d.) inoculated into C57BL/6 mice to generate OVA + tumors. When the tumor mass became large (7-8 mm), the tumor-bearing mice were intravenously injected with indicated CD8 + T-cell subsets. Anti-tumor activity mediated by the transferred cells was determined by measuring tumor size in perpendicular diameters. Tumor volume was calculated by the following formula: tumor volume = 0.4 3 length (mm) 3 [width (mm)] 2 .
Cytokine capture assay
The method for cytokine capture assay was described previously (17) . Briefly, for cytokine capture complex, biotin-IL-17 mAb (TC11-8H4.1; BD Biosciences) or biotin-IFN-c mAb (R4-6A2; BD Biosciences) were mixed with biotin-CD8a mAb (53-6.7; BD Biosciences) in a 3:1 molar ratio. Avidin (Invitrogen) was added to the mixture and incubated in 4°C for 10 min. CD8 + T cells were stimulated by platebounded anti-CD3 mAb (2 lg ml À1 ) and anti-CD28 mAb (2 lg ml À1 ) for 3 h. Cells were washed in PBS and incubated with the capture complex in 4°C for 10 min. After washed by PBS, cells were incubated in 37°C for 1 h and 30 min on a rotator, washed again and stained by PE-Cy7-CD45.1 mAb (A20; eBioscience), 7-AAD, PE-IL-17 mAb (TC11-18H10; BD Biosciences) and APC-IFN-c mAb (XMG1.2; BD Biosciences) for 10 min. Each CD8 + T-cell subsets were sorted using FACSAria.
Enzyme-linked immunosorbent assay
Cytokine levels in culture supernatant were measured by OptEIA TM IFN-c (BD Biosciences) and Ready-SET-Go TM mouse IL-17A (eBioscience) ELISA kits according to the manufacturers' directions.
Statistics
Statistical significance was calculated by two-tailed Student's t-test. A P-value <0.05 was considered significant in the present experiments and indicated with an asterisk.
Results
Tc17 cells exhibit no significant cytotoxicity in contrast to Tc1 cells
Naive CD8 + T cells from OT-1 TCR-transgenic mice were polarized into Tc17 or Tc1 cells under Tc17-or Tc1 culture conditions and their cytokine producibility and mRNA expression of transcription factors were determined on day 4. Tc17 cells expressed high levels of IL-17A and RORct, whereas Tc1 cells produced IFN-c and T-bet as expected (Fig. 1A and data not shown) . Tc1 cells showed strong cytotoxicity in parallel with mRNA expression of cytotoxic factors, perforin and granzyme B, whereas Tc17 cells exhibited neither strong cytotoxicity nor expression of cytotoxic factors ( Fig. 1B and C) . These data were consistent with previous investigations, which suggested that Tc17 cells are noncytotoxic (18) .
IL-12-converted IFN-c-producing Tc17 cells plastically differentiated from Tc17 cells
It is of great importance to elucidate the function of IFNc-producing Tc17 cells because Tc17 cells have been reported to show anti-tumor activity in IFN-c-dependent manner (10) . Therefore, we established a method to convert Tc17 cells into were comparable with the levels of these cytokines in the Tc17 and Tc1 subset, respectively (Fig. 2B) . Interestingly, IL-12-converted Tc17 cells expressed both RORct and T-bet, suggesting that these two master transcription factors, which were thought to be exclusively expressed in Tc17 and Tc1 cells (19, 20) , respectively, may be expressed and function simultaneously in IL-12-converted Tc17 cells (Fig. 2C) .
Cytotoxic function of IL-12-converted IFN-c-producing Tc17 cells
As shown in Fig. 1 , Tc17 cells exhibited no significant cytotoxicity in contrast to Tc1. However, IL-12-converted Tc17 cell population produced high levels of IFN-c, which is known to be critically involved in CTL induction. Therefore, we next analyzed whether IL-12-converted Tc17 cells possess cytotoxicity. As shown in Fig. 3(A) , IL-12-converted Tc17 cells exhibited high cytotoxicity against 51 Cr-labeled EG-7 tumor cells similar to Tc1 cells, whereas Tc17 cells exhibited no strong cytotoxicity. Furthermore, we investigated anti-tumor activity of IL-12-converted Tc17 cells in vivo using C57BL/6 mice inoculated with EG-7 tumor cells. When IL-12-converted Tc17 cells were transferred into EG-7-bearing mice, they strongly rejected the tumor, similar to Tc1 cells. However, such strong anti-tumor activity was not observed in mice that received Tc17 cells (Fig. 3B and C) . These data indicate that non-cytotoxic Tc17 cells possess the plasticity to differentiate into highly cytotoxic IFN-c-producing Tc17 cell populations when exposed to IL-12.
IL-17 and IFN-c double-producing Tc17/IFN-c cells were originated from Tc17 cells
Since cytotoxic IL-12-converted Tc17 cells are induced from Tc17 cell populations by IL-12 signaling, we next examined whether Tc17 cells is actually converted into IL-17/IFN-c double-producing cells using naive CD8 + T cells isolated from IL-17A-EGFP reporter mice. Tc17 cells induced from IL-17A-EGFP reporter mice were separated into GFPpositive and -negative cells (Fig. 4A and B) . To determine the precursors for IL-17/IFN-c double-producing cells, Tc17-conditioned cells were cultured with IL-12 to convert them into IFN-c producers. As a result, most of the IFN-cproducing cells were derived from the GFP-positive subset, indicating that IL-17/IFN-c double-producing cells are converted from the IL-17-producing GFP-positive cells (Fig.  4C) . Since GFP-negative populations were still able to respond to IL-12 and produce large amounts of IFN-c, it appeared that these cells were not exhausted or in a quiescent state (data not shown). These data strongly suggest that Tc17 cells were highly plastic and that IL-17/IFN-c double-producing cells were converted from the IL-17-producing cell subset, which was consistent with previous reports (20, 21) . (Fig. 5A) . To determine whether IL-17/IFN-c-DP cells, the major IL-12-converted Tc17 cell population, exhibit cytotoxicity against tumor, IL-17-SP, IL-17/IFN-c-DP, IFN-c-SP and IL-17/IFN-c-DN cells were isolated by a well-established cytokine capture assay system (17) . Following cytokine capture assay, cells were further isolated by flow cytometry (Fig. 5B) . As shown in Fig. 5(C) , we initially demonstrated that the isolated IL-17/ IFN-c DP cells exhibited strong cytotoxicity as well as IFNc-SP cells. However, IL-17-SP and IL-17/IFN-c-DN subsets showed greatly lower cytotoxic functions. Since the major population of IL-12-converted Tc17 cells is IL-17/IFN-c-DP cells rather than IFN-c-SP cells ( Fig. 2A) , it may be possible that the cytotoxic function of IL-12-converted Tc17 cells is largely derived from IL-17/IFN-c-DP cells rather than Tc1-like IFN-c-SP cells. Collectively, these data indicate that IL-17/IFN-c-DP (Tc17/IFN-c) cell is a novel CTL subset when Tc17 cells are physiologically converted into IFN-c producers under the influence of IL-12 signaling.
Direct evidence that
Discussion
Since IL-17-producing T h -cell subsets were discovered, many investigators have pursued the source and the function of IL-17 in the immune defense system. In addition to T h 17 cells, it is now accepted that IL-17 is produced by various types of cells such as CD8 + T cells, NKT, NK, cdT and LTi-like cells (16, (22) (23) (24) (25) . It has also been demonstrated that IL-17 plays critical roles in various immune diseases such as infectious diseases, autoimmune diseases, allergic diseases and in tumor immunity (16, (26) (27) (28) (29) (30) (31) . Although the critical role of T h 17 cells in immunoregulation has been elucidated, the precise role of Tc17 remains unclear. In this paper, we initially indicate direct evidence that IL-17 and IFN-c double-producing Tc17 (Tc17/IFN-c) cells are novel CTL subset, which can lyse tumor cells as well as Tc1-like cells plastically converted from Tc17 cells.
It has been demonstrated that IL-17 is a tumor-growth promoting factor (protumor) via up-regulated angiogenesis (8, Novel cytotoxic Tc17/IFN-c subset 757 29, 30, 32, 33) . In our previous paper, we have demonstrated that IL-17-producing cd T cells, but not CD4 + and CD8 + T cells, were the major source of IL-17, which promotes the growth of tumor cells (34) . In consistent with previous reports, spleen cd T cells revealed cytotoxicity against tumor cells, though tumor-infiltrating IL-17-producing cd T cells lost their cytotoxicity by the influence of immunosuppressive factor such as TGF-b and IL-6, which are produced at the tumor local site (5, 35) . In this paper, we confirmed that also Tc17 cells, which are induced under the influence of TGF-b and IL-6, do not express cytotoxic molecules (perforin and granzyme B) and do not exhibit strong cytotoxicity (Fig. 1) . Notably, it has been demonstrated that Tc17 cells exhibited anti-tumor activity in IFN-c-dependent manner (10, 12) . Hinrichs and colleagues (10) explained this result that IFN-c-producing Tc1-like cells, which were seem to be plastically converted from Tc17 cells, exhibited strong cytotoxicity for eradication of tumor cells. This conversion of Tc17 cells into Tc1-like cells may be due to epigenetic modifications as seen in T h 17 cells (19) , appearing to be critical for the acquisition of the anti-tumor feature for Tc17 cells in tumor immunity.
In this paper, we established a novel method that noncytotoxic Tc17 cells plastically convert into cytotoxic Tc17/ IFN-c cells by IL-12 signaling. IL-12-converted Tc17 cells showed strong anti-tumor activity both in vitro and in vivo (Fig. 3) . In our culture system, IL-17/IFN-c double-producing Tc17/IFN-c cells, but not IFN-c single-producing Tc1-like cells were the major IFN-c-producing cells in IL-12-converted Tc17 cells in contrast to previous results (10) . Therefore, our conversion method is suitable to analyze the precise role of Tc17/ IFN-c cells, which functional feature has never been evaluated in CD8
+ T cells. Although Tc17 converted-Tc1-like cells were seem to exhibit anti-tumor activity IFN-c-dependently, it still remains unclear whether Tc17/IFN-c cells act as anti-tumor effector cells (10, 12) . As shown in Fig. 5 , we initially isolated IL-17/IFN-c double-producing Tc17/IFN-c cells from IL-12-converted Tc17 cells by cytokine capture methods, and indicated direct evidence that Tc17/IFN-c cells are novel CTL subset, which exhibit cytotoxicity as well as Tc1-like cells. We conclude that Tc17 cells show no strong cytotoxicity, whereas plastically changed Tc17/IFN-c cells function as strong anti-tumor effector cells.
It remains unclear why Tc17/IFN-c cells can produce both IL-17 and IFN-c, which is exclusively regulated by distinct transcription factors, such as RORct and T-bet. Mukasa and colleagues (19) have clearly shown that the conversion of T h 17 cells into IFN-c-producing cells by IL-12 is due to histone remodeling of Il17a and Ifng loci, which is strongly induced by STAT4 and T-bet, resulting in inhibition of RORct expression for shutdown of Type 17 immune responses. Bending and colleagues (36) have reported that T h 17 cells, as responses to IL-12 treatment, remodel chromatin methylation degrees of Il12rb2 loci to a repressive state, allowing these cells to acquire extensive Type 1 features. Furthermore, recent report has elucidated the sophisticated mechanism how transcription factor RORct and T-bet are exclusively regulated in CD4 + T cells (20) . These investigations collectively support the fact that Type 17-and Type 1-immune responses are in mutually exclusive relationship. However, we have shown that IL-12-converted Tc17 cell population express mRNAs for both IL-17 and IFN-c in contrast to Tc17 and Tc1 cells, where they only express their signature cytokine (Fig. 2B) . Moreover, mRNAs for RORct and T-bet are also co-expressed in IL-12-converted Tc17 cells (Fig. 2C) . We have confirmed that the isolated Tc17/ IFN-c cells also express both RORct and T-bet, well matching with the data that Tc17/IFN-c cells actually expressing IFN-c while retaining their ability to produce IL-17, and moreover, acquiring cytotoxic functions by IL-12 signaling (Fig. 5C and data not shown). We are now investigating the detail molecular mechanisms underlying conversion of Tc17 cells into Tc17/IFN-c cells, which may be strongly regulated by epigenetic modifications.
Previously, we have demonstrated that Tc17/IFN-c cells were induced in our established Tc17-dependent colitis mechanisms (16) . We have also reported that IFN-c-producing T h 17 cells were infiltrated into lung during airway hyperresponsiveness (31) . These findings, taken together with previous reports, indicate that Tc17/IFN-c cells as well as T h 17/IFN-c cells, which are converted from T h 17/Tc17 cells, might act as effector cells in various immune diseases (14) . Therefore, we believe that our identified novel CTL subsets, Tc17/IFN-c cells, will play a crucial role as final effector cells with cytotoxicity in the tumor microenvironment. 
